CurrentCignaPolicy IP0066

Muscular Dystrophy - Viltepso

Defines medical necessity criteria, documentation, coverage duration, exclusions, and coding for viltolarsen (Viltepso) for treatment of Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyMuscular Dystrophy - Viltepso

Policy CodePolicy IP0066

Change TypeRevised criteria and title

Effective DateOct 15, 2025

Next Review Date

Key ActionSubmit documentation showing diagnosis of DMD and a confirmed pathogenic or likely pathogenic DMD variant amenable to exon 53 skipping; documentation may include chart notes, lab tests, claims records, or other information.

SourceLink

POLICY UPDATE CHANGES

Policy title updated from 'Viltolarsen' to 'Muscular Dystrophy - Viltepso' and DMD criteria split between Initial Therapy and Patient is Continuing Therapy; 'mutation' wording updated to 'pathogenic or likely pathogenic variant'; criteria for continuing therapy added.

Updated review date, disclaimer, refreshed background and references, addition of change history (Selected Revision Date 12/15/2024).

Annual Revision date set to 10/15/2025 in revision history.

1Approved Indication (DMD exon 53 skipping)

6 moAuthorization Duration

J1427Billable HCPCS Code

Concurrent agents

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Scope: Defines medical necessity criteria, documentation, coverage duration, exclusions, and coding for viltolarsen (Viltepso) for treatment of Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping for Cigna-administered health benefit plans.

Subject: Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy. Policy Number: IP0066. Coverage stance: covered_with_criteria. Effective/Last review dates: Effective 2025-10-15, Last review 2024-12-15.

Brief summary: Viltepso is covered with criteria for patients with Duchenne muscular dystrophy who have a confirmed pathogenic or likely pathogenic DMD variant amenable to exon 53 skipping; authorization is granted with specified documentation, age, and functional requirements.

Policy summary

Policy NumberIP0066

PayerCigna

Effective Date2025-10-15

Last Review2024-12-15

StatusCURRENT

Coverage Stancecovered_with_criteria

Approval Duration6 months (initial and continuing therapy approvals)

Evidence summary: Viltepso received accelerated approval based on an observed increase in dystrophin in skeletal muscle. Approximately 8–10% of DMD patients have variants amenable to exon 53 skipping.

Medical Necessity Criteria

FDA-Approved Indication - Duchenne Muscular Dystrophy (DMD)

Viltolarsen (Viltepso) is considered medically necessary when the following are met:

ANY of the following

A. Initial Therapy
- Diagnosis of Duchenne muscular dystrophy (DMD) [Documentation Required]
- Patient has a confirmed pathogenic or likely pathogenic variant of the DMD gene that is amenable to exon 53 skipping
- Patient is less than 10 years of age at start of therapy
- Patient is able to walk

Not Medically Necessary / Exclusions

Conditions Not Covered

Not medically necessary uses / exclusions

ALL of the following

Viltepso for any other use is considered not medically necessary
Concurrent use with other exon-skipping DMD agents (for example, Amondys 45, Exondys 51, or Vyondys 53) is not covered
No clinical evidence to support concurrent use

Denial Risk

Concurrent exon‑skipping agents may be denied

Claims for Viltepso used at the same time as other exon‑skipping DMD agents may be denied as not medically necessary. The policy explicitly prohibits concurrent use with other exon‑skipping agents and cites examples of affected therapies.

Coding

HCPCS for viltolarsenHCPCSCovered

J1427

Injection, viltolarsen, 10 mg

Billing Rule

Billing code and approval duration

The billable HCPCS code for Viltepso (viltolarsen) is J1427 (Injection, viltolarsen, 10 mg). When prior authorization is obtained and criteria are met, approvals are issued for a six‑month duration.

J1427

Provider Actions

Prior Authorization

Prior authorization and approval duration

Prior authorization is required per plan procedures. When criteria are met, approvals are issued for 6 months for both initial and continuing therapy. Use HCPCS code J1427 for viltolarsen when requesting authorization.

J1427

Documentation Required

Confirm diagnosis and genetic testing

Submit documentation demonstrating diagnosis of Duchenne muscular dystrophy (DMD) and a confirmed pathogenic or likely pathogenic DMD gene variant amenable to exon 53 skipping. Acceptable documentation may include chart notes, laboratory/genetic test results, claims records, and other information per the policy's Documentation Required definition.

Chart notes
Laboratory/genetic test results
Claims records

Background

Background: Viltepso (viltolarsen) is an antisense oligonucleotide designed to bind exon 53 of dystrophin pre-mRNA to induce exon 53 skipping and restore the reading frame, producing a shortened but partially functional dystrophin protein.

Regulatory status: Viltepso was approved via accelerated approval for the treatment of DMD in patients with DMD gene variants amenable to exon 53 skipping based on increased dystrophin in skeletal muscle. Continued FDA approval may be contingent on verification of clinical benefit in a confirmatory trial.

Required thresholds

Age at therapy start< 10 years

Baseline functional statusPatient is able to walk (ambulatory)

Baseline 6MWTBaseline 6-minute walk test (6MWT) results must be submitted for ambulatory patients

Evidence and Definitions

Evidence rows: 1) Indication basis: Accelerated approval based on an increase in dystrophin in skeletal muscle. 2) Proportion amenable: Approximately 8–10% of DMD patients have variants amenable to exon 53 skipping.

Documentation Required: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information demonstrating that the coverage criteria are met (for example, evidence of DMD diagnosis and genetic testing showing a pathogenic or likely pathogenic DMD variant amenable to exon 53 skipping).

Revision History

2024-12-15selected_revisionLatest

Updated review date, disclaimer, refreshed background and references, and added change history (Selected Revision).

2025-10-15annual_revision

Policy title updated from 'Viltolarsen' to 'Muscular Dystrophy - Viltepso'; DMD criteria split between Initial Therapy and Patient is Continuing Therapy; wording 'mutation' updated to 'pathogenic or likely pathogenic variant'; criteria for Continuing Therapy added (approvals for 6 months).

2025-10-15

Policy Summary

PayerCigna

PolicyMuscular Dystrophy - Viltepso

Policy CodePolicy IP0066

Change TypeRevised criteria and title

Effective DateOct 15, 2025

Next Review Date

SourceLink

On This Page

Baseline 6 minute walk test (6MWT) results must be submitted

The medication is being prescribed by, or in consultation with, a neurologist, neuromuscular specialist, or by a Muscular Dystrophy Association (MDA) clinic

B. Continuing Therapy

Diagnosis of Duchenne muscular dystrophy (DMD) [Documentation Required]
Patient has a confirmed pathogenic or likely pathogenic variant of the DMD gene that is amenable to exon 53 skipping
Patient was less than 10 years of age at start of therapy
Patient is able to walk
The medication is being prescribed by, or in consultation with, a neurologist, neuromuscular specialist, or by a Muscular Dystrophy Association (MDA) clinic

Approval Duration

Length of authorization when criteria met

ALL of the following

Initial Therapy: Approve for 6 months if Initial Therapy criteria (A.i–v) are met
Continuing Therapy: Approve for 6 months if Continuing Therapy criteria (B.i–v) are met

Examples: Amondys 45, Exondys 51, Vyondys 53

Other supporting clinical information

Documentation Required

Baseline 6MWT for ambulatory patients

For initial therapy, providers must submit baseline 6‑minute walk test (6MWT) results to document ambulatory status as part of the initial authorization request. The policy requires baseline 6MWT results under the Initial Therapy criteria (patient must be able to walk).

Baseline 6MWT results demonstrating patient is ambulatory

Documentation Required

Specialist involvement required

The prescriber must be a neurologist, neuromuscular specialist, or the medication must be prescribed in consultation with such a specialist, or by a Muscular Dystrophy Association (MDA) clinic. Documentation of specialist involvement should be provided with the request.

Prescriber is a neurologist or neuromuscular specialist
OR prescription in consultation with a neurologist/neuromuscular specialist
OR prescription by an MDA clinic

Denial Risk

Concurrent exon‑skipping agents prohibited

Claims for Viltepso used concurrently with other exon‑skipping agents may be denied as not medically necessary. The policy states there is no clinical evidence to support concurrent use and lists examples of exon‑skipping agents for which concurrent therapy is not covered.

Examples: Amondys 45, Exondys 51, Vyondys 53

approval_duration_update

Approval duration defined: both Initial Therapy and Continuing Therapy approvals set to 6 months when criteria are met.

2025-10-15criteria_split

Initial Therapy and Continuing Therapy criteria explicitly delineated, including requirement that patient was <10 years at therapy start and is ambulatory for continuing therapy.